247 related articles for article (PubMed ID: 26179644)
1. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
[TBL] [Abstract][Full Text] [Related]
2. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
[TBL] [Abstract][Full Text] [Related]
3. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
Suh HS; Kim JA; Lee IH
BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
5. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
Kwon HY; Hong JM; Godman B; Yang BM
Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
[TBL] [Abstract][Full Text] [Related]
6. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
de Jager H; Suleman F
Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
[TBL] [Abstract][Full Text] [Related]
7. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
Kang SO; Kim SJ; Park S; Jang SI; Park EC
Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
[TBL] [Abstract][Full Text] [Related]
8. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
Lee IH; Bloor K; Hewitt C; Maynard A
Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
[TBL] [Abstract][Full Text] [Related]
9. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
[TBL] [Abstract][Full Text] [Related]
10. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
11. Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea.
Kim JY; Kim SJ; Nam CM; Moon KT; Park EC
Eur J Public Health; 2018 Apr; 28(2):209-214. PubMed ID: 29579210
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
13. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
14. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea.
Kwon HY; Bae S; Choi SE; Park S; Lee EK; Park S; Kim J
Health Policy; 2019 Apr; 123(4):388-392. PubMed ID: 30503763
[TBL] [Abstract][Full Text] [Related]
15. Toward safer prescribing: evaluation of a prospective drug utilization review system on inappropriate prescriptions, prescribing patterns, and adverse drug events and related health expenditure in South Korea.
Kim SJ; Han KT; Kang HG; Park EC
Public Health; 2018 Oct; 163():128-136. PubMed ID: 30145461
[TBL] [Abstract][Full Text] [Related]
16. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
17. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
[TBL] [Abstract][Full Text] [Related]
18. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis.
Fretheim A; Håvelsrud K; MacLennan G; Kristoffersen DT; Oxman AD
PLoS Med; 2007 Jul; 4(7):e232. PubMed ID: 17622192
[TBL] [Abstract][Full Text] [Related]
19. Improving cost-effectiveness of hypertension management at a community health centre.
Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
[TBL] [Abstract][Full Text] [Related]
20. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
Bae G; Park C; Lee H; Han E; Kim DS; Jang S
BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
